

IN THE CLAIMS

Please replace claims 6, 7, 9, 10, 12, and 25 with new amended claims 6, 7, 9, 10, 12, and 25 as follows below. A marked up version of the amended claims to show the changes made is attached hereto.

6. Process according to claim 1, wherein the process is performed on mammal spermatozoa.

Q1 10048013-042902
7. Process according to claim 1, wherein the PI3K inhibitor is selected from the group consisting of 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), wortmannin, quercetin, and derivatives and analogues thereof.

9. Process according to claim 1, wherein spermatozoa are treated with an amount of PI3K inhibitor in the range of about 0.01 to 1000 μ M, about 5 to 500 μ M, or about 10 to 100 μ M.

Q2
10. Process according to claim 1, wherein treating the spermatozoa with the PI3K inhibitor comprises incubating the spermatozoa for a period of time in the range of about 30 minutes to 10 hours or about 1 to 8 hours or about 2 to 6 hours at a temperature of around 37°C.

Q3 12. Spermatozoa obtainable by the process according to claim 1.

Q4 25. Medium according to claim 21, comprising an amount of PI3K inhibitor in the range of about 0.01 to 1000 μ M, about 5 to 500 μ M, or about 10 to 100 μ M.

Please cancel claims 13-18 and add new claims 26-28 as follows:

10048013 042902
--26(New). The method according to claim 19, 2h34in the PI3K inhibitor is selected from the group consisting of 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), wortmannin, quercetin, and derivatives and analogues thereof.--

--27(New). The method according to claim 26, wherein the PI3K inhibitor is LY294002.--

--28(New). The process according to claim 6, wherein the mammal spermatozoa is human spermatozoa.--